{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:46Z","timestamp":1786996786625,"version":"build-2736575974"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["22TACT01"],"award-info":[{"award-number":["22TACT01"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["101172722"],"award-info":[{"award-number":["101172722"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["101172788"],"award-info":[{"award-number":["101172788"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.003","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:15:27Z","timestamp":1749755727000},"page":"463-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiopharmaceuticals in Prostate Cancer: General Considerations and Utility in Combination With EBRT"],"prefix":"10.1016","volume":"35","author":[{"given":"Caner","family":"Civan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Guberina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Krafft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10437","key":"10.1016\/j.semradonc.2025.04.003_bib0001","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.003_bib0002","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","article-title":"PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials","volume":"28","author":"Ramnaraign","year":"2023","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.003_bib0003","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00259-016-3415-4","article-title":"The EANM practice guidelines for bone scintigraphy","volume":"43","author":"Van den Wyngaert","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.003_bib0004","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.003_bib0006","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10276","key":"10.1016\/j.semradonc.2025.04.003_bib0007","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.003_bib0008","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.003_bib0009","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.003_bib0010","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12149-020-01474-7","article-title":"Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET\/CT in prostate cancer?","volume":"34","author":"Simsek","year":"2020","journal-title":"Ann Nucl Med"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.003_bib0011","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00259-015-3138-y","article-title":"(18)F-NaF PET\/CT: EANM procedure guidelines for bone imaging","volume":"42","author":"Beheshti","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.003_bib0012","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2967\/jnumed.115.166512","article-title":"Prospective Study Evaluating Na18F PET\/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer","volume":"57","author":"Apolo","year":"2016","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.003_bib0013","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3390\/biomedicines10102533","article-title":"The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer","volume":"10","author":"Li","year":"2022","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.003_bib0014","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2967\/jnumed.117.207373","article-title":"A Prospective Comparison of (18)F-Sodium Fluoride PET\/CT and PSMA-Targeted (18)F-DCFBC PET\/CT in Metastatic Prostate Cancer","volume":"59","author":"Harmon","year":"2018","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.003_bib0015","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/MNM.0000000000001621","article-title":"Bone metastases in prostate cancer - Gallium-68-labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET\/computed tomography - the better tracer?","volume":"43","author":"Agrawal","year":"2022","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0016","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13014-019-1359-0","article-title":"NaF PET\/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy","volume":"14","author":"Hardcastle","year":"2019","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.003_bib0017","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12149-022-01730-y","article-title":"Therapy-induced bone changes in oncology imaging with (18)F-sodium fluoride (NaF) PET-CT","volume":"36","author":"Ahmed","year":"2022","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.semradonc.2025.04.003_bib0018","article-title":"Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?","volume":"10","author":"Ouvrard","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.003_bib0019","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41391-018-0110-5","article-title":"Quantification of bone flare on (18)F-NaF PET\/CT in metastatic castration-resistant prostate cancer","volume":"22","author":"Weisman","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.003_bib0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2022.10.024","article-title":"Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer","volume":"83","author":"Bukavina","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.003_bib0021","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.003_bib0022","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"10231","key":"10.1016\/j.semradonc.2025.04.003_bib0023","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.003_bib0024","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.003_bib0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.003_bib0026","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.003_bib0027","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.04.003_bib0028","doi-asserted-by":"crossref","DOI":"10.1007\/s00066-025-02376-1","article-title":"Optimizing treatment for Gleason 10 prostate cancer: radiation dose escalation and (68)Ga-PSMA-PET\/CT staging","author":"Onal","year":"2025","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0029","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13014-018-1036-8","article-title":"Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET\/CT and MRI: a planning study based on histology reference","volume":"13","author":"Zamboglou","year":"2018","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.003_bib0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.003_bib0031","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.003_bib0032","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.euo.2024.09.015","article-title":"Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences","volume":"8","author":"van Altena","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.003_bib0033","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0034","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eururo.2024.01.012","article-title":"Impact of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.003_bib0035","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ijrobp.2022.04.048","article-title":"Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.003_bib0036","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2967\/jnumed.117.196683","article-title":"Treatment Outcomes from (68)Ga-PSMA PET\/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET","volume":"58","author":"Emmett","year":"2017","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0037","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s40644-024-00752-1","article-title":"Prognostic significance of a negative PSMA PET\/CT in biochemical recurrence of prostate cancer","volume":"24","author":"Harsini","year":"2024","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.semradonc.2025.04.003_bib0038","article-title":"Early and repetitive novel-tracer PET-guided stereotactic body radiotherapy for nodal oligorecurrent prostate cancer after definitive first-line therapy","author":"Gr\u00fcn","year":"2024","journal-title":"Strahlenther Onkol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.003_bib0039","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00066-024-02260-4","article-title":"Implementation of PET\/CT in radiation oncology-a patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation Oncology","volume":"200","author":"Wegen","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.semradonc.2025.04.003_bib0040","doi-asserted-by":"crossref","DOI":"10.2196\/60323","article-title":"A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study","volume":"10","author":"Janbain","year":"2024","journal-title":"JMIR Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14748","article-title":"Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer","volume":"6","author":"Zamboglou","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.003_bib0042","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/pros.24142","article-title":"Clinical parameters and nomograms for predicting lymph node metastasis detected with (68) Ga-PSMA-PET\/CT in prostate cancer patients candidate to definitive radiotherapy","volume":"81","author":"Onal","year":"2021","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.003_bib0043","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10162","key":"10.1016\/j.semradonc.2025.04.003_bib0044","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13014-023-02302-8","article-title":"Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer","volume":"18","author":"Mohan","year":"2023","journal-title":"Radiat Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.003_bib0046","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/RLU.0000000000003558","article-title":"Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET\/CT: TROD 09-004 Study","volume":"46","author":"Onal","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.semradonc.2025.04.003_bib0047","article-title":"(18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer","volume":"39","author":"Mesci","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.003_bib0048","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3390\/cancers11091348","article-title":"(18)F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"11","author":"Laudicella","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semradonc.2025.04.003_bib0049","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3389\/fonc.2019.01438","article-title":"Diagnostic Performance of PET\/CT Using 18F-FACBC in Prostate Cancer: A Meta-Analysis","volume":"9","author":"Bin","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.003_bib0050","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/diagnostics11020304","article-title":"18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis","volume":"11","author":"Biscontini","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.003_bib0051","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"(18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10288","key":"10.1016\/j.semradonc.2025.04.003_bib0052","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"(18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0053","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.semnuclmed.2023.06.004","article-title":"Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET\/CT?","volume":"54","author":"Vetrone","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.003_bib0054","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s12149-024-01978-6","article-title":"Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis","volume":"38","author":"Belge Bilgin","year":"2024","journal-title":"Ann Nucl Med"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.003_bib0055","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(24)00069-X","article-title":"(68)Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2\/3 imaging trial","volume":"25","author":"Duan","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.003_bib0056","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0057","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00259-024-06891-8","article-title":"Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [(68)Ga]Ga-\/[(18)F]F-PSMA-11\/-1007, [(68)Ga]Ga-FAPI-46 and 2-[(18)F]FDG PET\/CT: a pilot study","volume":"52","author":"Pabst","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"19","key":"10.1016\/j.semradonc.2025.04.003_bib0058","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.003_bib0059","first-page":"1952","article-title":"FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study","volume":"65","author":"Huang","year":"2024","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.003_bib0060","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2967\/jnmt.123.265936","article-title":"SNMMI Procedure Standard\/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases","volume":"51","author":"Pantel","year":"2023","journal-title":"J Nucl Med Technol"},{"issue":"16","key":"10.1016\/j.semradonc.2025.04.003_bib0061","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-21-0685","article-title":"Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer","volume":"27","author":"Turner","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.04.003_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110063","article-title":"A potential biomarker of radiosensitivity in metastatic hormone sensitive prostate cancer patients treated with combination external beam radiotherapy and radium-223","volume":"191","author":"Redmond","year":"2024","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.003_bib0063","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/cancers14041077","article-title":"Alpha-Emitter Radiopharmaceuticals and External Beam Radiotherapy: A Radiobiological Model for the Combined Treatment","volume":"14","author":"Sarnelli","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.003_bib0064","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.003_bib0065","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4_suppl","key":"10.1016\/j.semradonc.2025.04.003_bib0066","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2024.42.4_suppl.160","article-title":"Mature results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-na\u00efve men with oligometastatic prostate cancer to bone","volume":"42","author":"Tward","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0067","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12894-023-01202-z","article-title":"A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)","volume":"23","author":"Yoshida","year":"2023","journal-title":"BMC Urol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0068","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12885-020-07000-2","article-title":"A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)","volume":"20","author":"Hasan","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.003_bib0069","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ijrobp.2024.08.021","article-title":"Outcomes of RAdium-223 and SABR vs. SABR for oligomEtastatic prostate caNcerS \u2013 The RAVENS Phase II Randomized Trial","volume":"120","author":"Tran","year":"2024","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.003_bib0070","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.ijrobp.2024.07.2157","article-title":"Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone\/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP)","volume":"120","author":"Dandapani","year":"2024","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0071","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13550-015-0114-2","article-title":"Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study","volume":"5","author":"Ahmadzadehfar","year":"2015","journal-title":"EJNMMI Res"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.003_bib0072","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET\/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions","volume":"56","author":"Afshar-Oromieh","year":"2015","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.003_bib0073","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.003_bib0074","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3390\/biomedicines12102355","article-title":"Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview","volume":"12","author":"Caracciolo","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","article-title":"Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer","volume":"8","author":"L\u00fcckerath","year":"2018","journal-title":"EJNMMI Res"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.003_bib0076","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.7150\/thno.93249","article-title":"Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [(177)Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside","volume":"14","author":"Arbuznikova","year":"2024","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.003_bib0077","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/j.ijrobp.2023.06.891","article-title":"A Pilot Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for Oligometastatic Hormone Sensitive Prostate Cancer","volume":"117","author":"Imber","year":"2023","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.003_bib0078","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12885-023-10725-5","article-title":"Tolerability of concurrent external beam radiotherapy and [(177)Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment na\u00efve patients, phase I study (PROQURE-I trial)","volume":"23","author":"van der Sar","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.003_bib0079","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40291-024-00699-w","article-title":"Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes","volume":"28","author":"Nguyen","year":"2024","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.003_bib0080","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2967\/jnumed.119.234922","article-title":"Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors","volume":"61","author":"Wurzer","year":"2020","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.003_bib0081","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"Diagnostic Performance and Safety of Positron Emission Tomography with (18)F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)","volume":"84","author":"Surasi","year":"2023","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.003_bib0082","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2967\/jnumed.121.263371","article-title":"Synthesis and Preclinical Evaluation of (177)Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer","volume":"63","author":"Wurzer","year":"2022","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.003_bib0083","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-024-06959-5","article-title":"Experience of rescue therapy with [(177)Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [(177)Lu]Lu-PSMA-I&T","volume":"52","author":"G\u00e4ble","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.003_bib0084","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/pros.24137","article-title":"(225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis","volume":"81","author":"Ballal","year":"2021","journal-title":"Prostate"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.003_bib0085","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/RLU.0000000000003925","article-title":"225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: A Single-Center Experience","volume":"46","author":"Sanli","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.003_bib0086","doi-asserted-by":"crossref","DOI":"10.3390\/ph17081031","article-title":"Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy","volume":"17","author":"Winter","year":"2024","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:16:13Z","timestamp":1762355773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000311"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.003","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiopharmaceuticals in Prostate Cancer: General Considerations and Utility in Combination With EBRT","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}